Navigation Links
Carcinoid in Medical News

The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors

Bethesda, MD (June 25, 2009) The AGA Foundation for Digestive Health and Nutrition (FDHN) has named Michael Y. Choi , MD, the first recipient of the Mary Terese Hartzheim Award for Neuroendocrine Tumor Research. This new research award was created for young investigators interested in researching...

Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis

...Phase 2 clinical trials, LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome. Furthermore, LX4211 for diabetes has recently completed dosing i...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results

...tion of a Phase 2 study of LX1032 in patients with carcinoid syndrome," said Dr. Arthur T. Sands , president...on (FDA), into a Phase 2a study in patients with carcinoid syndrome . The Phase 2 clinical trial is designe...LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patient...

Carcinoid Cancer Foundation Sets Sights on Raising Awareness

...t the only cancers that catch victims by surprise. carcinoid cancer can go undetected for many years. Over 90% ...ectly diagnosed and treated for the wrong disease. carcinoid cancers are frequently diagnosed accidentally. carcinoid and related neuroendocrine tumors (NETs) grow slow...

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...future upon achievement of certain milestones related to NEBIDO(R) (in development for hypogonadism) and octreotide (in development for acromegaly and carcinoid syndrome), two of the Company's primary product candidates. The acquisition will be effected by means of a tender offer for all the outstanding shares...

Frost & Sullivan Recognizes Neotropix's Approach to the Treatment of Small Cell Lung Cancer and Neuroendocrine Cancers

...o address unmet needs in the treatment of adults with small cell cancer and carcinoid cancer. It can also potentially treat children with neuroblastoma, Wilms' t...ts from Phase I/II open label clinical trials, which included both SCLC and carcinoid cancer patients, found that the majority of patients responded to NTX-010 t...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

...reotide implant (in development for acromegaly and carcinoid syndrome), two of Indevus' primary product candida...keting and sale for the treatment of acromegaly or carcinoid syndrome. The tender offer is expected to com...thogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Abo...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in t...

Saturated Fats Linked to Cancer of Small Intestine

...ective study to examine the association between meat and fat intake and cancer of the small intestine. During the study, 60 adenocarcinomas and 80 carcinoid tumors of the small intestine were diagnosed among the participants, and an elevated risk for these cancers was associated with saturated fat intake, ...

Also in the Sept. 9 JNCI

...144 Experts Call for Renewed Efforts in Gastroenteropancreatic Neuroendocrine Tumors During a September 2007 summit on neuroendocrine and carcinoid tumor, clinicians and researchers presented the current standards of care and identified key areas that require investigation and development. Ove...
Carcinoid in Medical Technology

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan d...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown , senior vice president of clinical develop...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to inter...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...ning tumors (i.e., tumors that are associated with carcinoid syndrome due to the secretion of various hormones ...iarrhea/flushing episodes associated with advanced carcinoid tumors and profuse watery diarrhea associated with... used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive inte...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

...ood and Drug Administration (FDA), into a Phase 2a study in patients with carcinoid syndrome . Lexicon has identified the clinical trial sites for this study...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the mean...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal micr...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

...etween the endocrine (hormonal) system and the nervous system, and includes carcinoid tumors and pancreatic NETs. Treatment options for patients with NETs are li...utes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive intestinal peptide (VIP) secr...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

...AR Depot therapy on survival in pancreatic NET and carcinoid patients EAST HAN... mixture of tumors that include pancreatic NET and carcinoid tumors. The development of NET is not completely u...to treat the diarrhea and flushing associated with carcinoid syndrome. The active ingredient in Sandostatin L...

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

... the debilitating symptoms of this disease. About carcinoid Cancer carcinoid tumors, or carcinoids, originate in hormone-produc...h the number increasing over the past 20-30 years. carcinoid tumors that metastasize to the liver have a poor p...
Carcinoid in Medical Definition

Pathology

...ome - 5-alpha-reductase deficiency - Hypogonadism - Delayed puberty - Precocious puberty Other Autoimmune polyendocrine syndrome - carcinoid syndrome - Laron syndrome - Psychogenic dwarfism - Androgen insensitivity syndrome - Progeria v • d • e Nut...
Carcinoid in Medical Dictionary

Lung tumor

...r ... What Are the Key Statistics About Lung carcinoid Tumor ? ... to suspect you may have a lung carcinoid tumor , your doctor will use one or more ... ...s into adjacent tissues and ... Symptoms of a carcinoid lung tumor include coughing up blood, wheezing...

Gastrointestinal

...r, Fox Chase Cancer Center offers comprehensive care Gastrointestinal carcinoid tumors develop from a certain type of hormone -making ... A gastrointestinal carcinoid tumor may also produce hormones. ... Gastrointestinal bleeding inf...

Carcinoid tumor

... carcinoid is a slow-growing type of neuroendocrine tumour, ... in the cells of the neuroendocrine system. carcinoid tumors produce the vasoactive substance, serotonin. ... carcinoid tumors arising in the bronchi may be associa...

Carcinoid syndrome

... Other components of the carcinoid syndrome are diarrhea (probably caused by ... Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day. ... Learn about carcinoid syndrome , get support, and find treatment opt...
Carcinoid in Biological News

Society of Interventional Radiology Foundation awards $191,000 in grants

...nu Gaur, Harvard Medical School, Boston, Mass., "Hepatic Arterial Chemoembolization (HACE), Yttrium-90 Radioembolization and Drug-eluting Bead-HACE in carcinoid Metastases to the Liver." ...
Carcinoid in Biological Technology

Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032 , the...

EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study

Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the pre...

Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome

THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1032, an oral drug candidate for managing gastrointest...

Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Delcath Systems Granted Third Orphan Drug Designation

... the drug melphalan for the treatment of neuroendocrine tumors metastatic to the liver. The trial is treating patients with pancreatic islet-cell and carcinoid tumors at the National Cancer Institute in Bethesda, Maryland. Commenting on this orphan-drug designation, Richard L. Taney, President and CEO of Del...

Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week

...naging gastrointestinal symptoms associated with carcinoid syndrome . The presentations will take place at ...X1032 is entering a Phase 2 study in patients with carcinoid syndrome. For more information on these pro... candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel s...

Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its prop...

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L....
Carcinoid in Biological Dictionary

Intestine

...appendix G ... structure of the intestine varies greatly in ... Small Intestine Cancer Key Terms: Adenocarcinoma , Angiosarcoma , Carcinogen , carcinoid , Leiomyosarcoma , Liposarcoma , Lymphoma , Malignant , In anatomy, the intestine is that tubular portion of the Gastrointestinal tract ... In hu...
Other Tags
(Date:8/21/2014)... Black mothers are less likely than white moms to ... Hospitals in neighborhoods with many black residents do less ... white residents, a U.S. government study finds. Key ... medical centers where the black population is higher than ... and Prevention reported Thursday. These practices include efforts ...
(Date:8/21/2014)... 21, 2014 The W. Montague ... and a national voice in the elimination of ... disparities during the 112th National Medical Association’s (NMA) ... included: , John Ruffin, Ph.D, former Director of ... Disparities, whose life-long career and innovations have had ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
(Date:8/21/2014)... The report "Industrial Flue Gas Treatment Systems & ... Particulate Control, Mercury Control) by Application (Power Generation, ... Global Trends & Forecasts to 2019" defines and ... & services market with analysis and projection of ... The industrial flue gas treatment systems & services ...
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
Breaking Medicine News(10 mins):Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
(Date:8/20/2014)... -  Issue Serious allergic reactions to ... threatening for some children.    What you should ... food allergies and this number may be increasing, especially among ... to have food allergies.  The symptoms of ... to breathing difficulties and loss of consciousness. Symptoms can also ...
(Date:8/20/2014)... outcomes of approximately 3 million infants, a team of ... University of Massachusetts Medical School, have shown that newborn ... implemented across public health newborn screening programs. Data from ... issue of the Journal of the American Medical ... SCID in newborns is higher than previously thought and ...
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
Other Contents